Inaktiver Wert

Andere Sprachen Benitec Biopharma Limited Deutsche Boerse AG

Aktien

722783

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

Benitec Biopharma Reports Continued Durable Improvements in the Radiographic Assessments of Swallowing Efficiency and the Subject-Reported Outcome Instrument at the 180-Day Timepoint for First OPMD Subject Treated with Low-Dose BB-301 in Phase 1b/2a Study	15.07.
Benitec Biopharma Reports Continued Durable Improvements in the Radiographic Assessments of Swallowing Efficiency and the Subject-Reported Outcome Instrument at the 180-Day Timepoint for First OPMD Subject Treated with Low-Dose BB-Dose BB-301 in Phase 1b/2a Study	15.07.
Benitec Biopharma Announces Appointment of Kishen Mehta to its Board of Directors	01.07.
Benitec Biopharma Inc. Announces Appointment of Kishen Mehta to Its Board of Directors	01.07.
Benitec Biopharma Inc.(NasdaqCM:BNTC) added to Russell 3000E Index	01.07.
Benitec Biopharma Inc.(NasdaqCM:BNTC) added to Russell Microcap Index	01.07.
Benitec Biopharma Inc.(NasdaqCM:BNTC) added to Russell Microcap Value Index	01.07.
Benitec Biopharma Inc.(NasdaqCM:BNTC) added to Russell 3000E Value Index	01.07.
Benitec Biopharma Releases Third Quarter 2024 Financial Results and Provides Operational Update	13.05.
Benitec Biopharma : Releases Third Quarter 2024 Financial Results and Provides Operational Update - Form 8-K	13.05.
Benitec Biopharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	13.05.
Benitec Biopharma to Participate in the Citizens JMP Life Science Conference	01.05.
Benitec Biopharma Inc. announced that it has received $40.000019 million in funding from a group of investors	22.04.
Sector Update: Health Care Stocks Mixed in Late Afternoon Trading	18.04.
Top Midday Gainers	18.04.
Top Premarket Gainers	18.04.
Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study	18.04.
Benitec Biopharma Inc. Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study	18.04.
Benitec Biopharma Announces Oversubscribed Private Placement Financing of $40.0 Million	18.04.
Benitec Biopharma to Host Virtual R&D Day to Discuss BB-301 Clinical Program in Oculopharyngeal Muscular Dystrophy on April 18, 2024	09.04.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Benitec Biopharma Limited Deutsche Boerse AG

Aktien

722783

Andere Sprachen

Filter